There is no potential conflict of interest relevant to this article.
Estimation of absolute risk for prostate cancer using genetic markers and family history†
Article first published online: 26 JUN 2009
Copyright © 2009 Wiley-Liss, Inc.
Volume 69, Issue 14, pages 1565–1572, 1 October 2009
How to Cite
Xu, J., Sun, J., Kader, A. K., Lindström, S., Wiklund, F., Hsu, F.-C., Johansson, J.-E., Zheng, S. L., Thomas, G., Hayes, R. B., Kraft, P., Hunter, D. J., Chanock, S. J., Isaacs, W. B. and Grönberg, H. (2009), Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate, 69: 1565–1572. doi: 10.1002/pros.21002
- Issue published online: 24 AUG 2009
- Article first published online: 26 JUN 2009
- Manuscript Accepted: 20 MAY 2009
- Manuscript Received: 11 MAY 2009
- National Cancer Institute. Grant Numbers: CA105055, CA106523, CA95052
- Department of Defense. Grant Number: PC051264
- Swedish Cancer Society (Cancerfonden)
- Swedish Academy of Sciences (Vetenskapsrådet)
- early detection;
Multiple DNA sequence variants in the form of single-nucleotide polymorphisms (SNPs) have been found to be reproducibly associated with prostate cancer (PCa) risk.
Absolute risk for PCa among men with various numbers of inherited risk alleles and family history of PCa was estimated in a population-based case–control study in Sweden (2,893 cases and 1,781 controls), and a nested case–control study from the Prostate, Lung, Colon and Ovarian (PLCO) Cancer Screening Trial in the U.S. (1,172 cases and 1,157 controls).
Increased number of risk alleles and positive family history were independently associated with PCa risk. Considering men with 11 risk alleles (mode) and negative family history as having baseline risk, men who had ≥14 risk alleles and positive family history had an odds ratio (OR) of 4.92 [95% confidence interval (CI): 3.64–6.64] in the Swedish study. These associations were confirmed in the U.S. population. Once a man's SNP genotypes and family history are known, his absolute risk for PCa can be readily calculated and easily interpreted. For example, 55-year-old men with a family history and ≥14 risk alleles have a 52% and 41% risk of being diagnosed with PCa in the next 20 years in the Swedish and U.S. populations, respectively. In comparison, without knowledge of genotype and family history, these men had an average population absolute risk of 13%.
This risk prediction model may be used to identify men at considerably elevated PCa risk who may be selected for chemoprevention. Prostate 69: 1565–1572, 2009. © 2009 Wiley-Liss, Inc.